Analysis on the use of medicines in treatment of benign prostatic hyperplasia in sample hospitals under the national volume-based procurement policy
10.12206/j.issn.2097-2024.202408031
- VernacularTitle:国家集中带量采购政策下样本医院良性前列腺增生治疗药物使用情况分析
- Author:
Rui LI
1
;
Qianqian ZHANG
2
;
Ruidong WANG
3
;
Xiaofeng GAO
1
Author Information
1. Department of Urology, The First Affiliated Hospital of Naval Medical University, Shanghai 200433, China.
2. Department of Pharmacy, Luodian Hospital, Baoshan District, Shanghai 201908, China.
3. Clinical Research Center, The Third Affiliated Hospital of Naval Medical University, Shanghai 200438, China.
- Publication Type:PharmacyAdministration
- Keywords:
national centralized drug volume-based procurement;
drugs for the treatment of benign prostatic hyperplasia;
defined daily doses;
defined daily dose cost
- From:
Journal of Pharmaceutical Practice and Service
2025;43(1):41-46
- CountryChina
- Language:Chinese
-
Abstract:
Objective To explore the impact of national volume-based procurement policies on the use of medicines in treatment of benign prostatic hyperplasia （BPH） and provide data support for the rational clinical use of medicines in BPH treatment. Methods Data on the use of BPH treatment medications from 2019 to 2023 were extracted from the Chinese Medicine Economic Information Network （CMEI）, covering 892 hospitals （including 645 tertiary hospitals and 247 secondary hospitals）. The changes in various indicators, including the consumption sum, Defined daily doses （DDDs）, Defined daily dose cost （DDDc）, and the ranking ratio （B/A） of these drugs were analyzed and compared. Results From 2019 to 2023, due to the influence of relevant policies, the overall consumption sums of medicines used in the sample hospitals in BPH treatment showed a trend of decreasing first and then rising steadily. The DDDs showed an overall upward trend, while the DDDc demonstrated a gradual decline. Tamsulosin and finasteride consistently ranked first and second in DDDs. The B/A value for tamsulosin was significantly higher than that of other BPH treatment medications. Conclusion The implementation of national centralized drug volume-based procurement policies and other policies from 2019 to 2023 had effectively reduced the economic burden of patients with benign prostatic hyperplasia. Tamsulosin and finasteride, which had the highest B/A in the two categories of α-blockers and 5α-reductase inhibitors, dominated the market for BPH treatment. The clinical use of BPH treatment medications was relatively rational.
